How Clarity’s Cu-SAR-Bombesin Unveils Hidden Prostate Cancer Recurrence

• Cu-SAR-Bombesin targets GRPR, a receptor expressed in up to 100% of prostate cancers including PSMA-negative cases
• Phase II SABRE trial enrolled 53 patients with biochemical recurrence and negative/equivocal standard imaging
• Lesions detected in approximately 35% of patients on same-day imaging, with 100% biopsy-confirmed true positives
• Agent was safe and well tolerated with only mild, transient adverse events